Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

  • Teri J. Mauch
  • , Michael R. Chladek
  • , Spero Cataland
  • , Shruti Chaturvedi
  • , Bradley P. Dixon
  • , Katherine Garlo
  • , Christoph Gasteyger
  • , Anuja Java
  • , Jorge Leguizamo
  • , Lucy Lloyd-Price
  • , Tan P. Pham
  • , Tara Symonds
  • , Ioannis Tomazos
  • , Yan Wang

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Neuroscience